Religare's research report on Cadila Healthcare
CDH’s Q1FY17 adjusted margins of 21.1% were marginally lower than our estimate (21.6%), but were nevertheless commendable given lower HCQS revenues and weak domestic growth. Management believes that the HCQS impact is largely in the base and margins should improve as product launches pick up over ensuing quarters (12-15 launches by Dec’16). While there was no additional clarity on Moraiya resolution, management expects to invite the USFDA for a re-inspection soon. BUY; Mar’17 TP Rs 370.
We retain estimates and maintain our BUY rating on the stock. The Moraiya facility resolution is the next key stock trigger, in our view. For all recommendations, click here Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
